1FW

20/	- "	-	Applic	ation Number	10/807,36	52	
TRANS	MITTAL		Filing	Date	March 22	, 2004	
FC)RM		First N	lamed Inventor	Thierry G	lauser	
(to be used for all corres	spondence after in	itial filing)	Group	Art Unit	1615		
			Exami	iner Name	Unknown		
Total Number of Pages (excluding references)	in This Submission	13	Attorn	ey Docket Number	50623.35	1	
		ENCLO	OSURES	(check all that apply)	•		
Deposit Account 07-	1850	Assigni	ment Pap Application	ers	After A	llowance Communication	
Postage Paid Return	Postcard			ormal Sheets with Drawings Transmittal		Communication to Board Is and Interferences	
Amendment / Respo	nse	Licensi	ng-relate	d Papers		Communication to Group Notice, Brief, Reply Brief)	
Amendment Transmi duplicate)	ittal Letter (in	Petition	1		Proprie	etary Information	
Affidavits/declara	ation(s)	Petition to Convert to a Provisional Application			Status Letter		
Petition for Extension months) (in duplicate		Power of Attorney, Revocation Change of Correspondence Address				Enclosure(s) identify below):	
Information Disclosur (in duplicate) with Fo	re Statement orm PTO-1449	Terminal Disclaimer Request for Refund			Foreign Patent Documer Other Documents		
Express Mail Label N		CD, Number of CD(s)					
Certified Copy of Price	ority	Rema		· ·	<u> </u>		
Response to Missing Incomplete Application		,					
Response to Mis Parts under 37 C 1.52 or 1.53							
	SIGNA	TURE OF A	APPLICA	ANT, ATTORNEY, O	R AGENT		
	quire, Sanders & I haoyang Li, Ph.D.						
Signature		13					
Date Ju	uly 8, 2004						
		CE	RTIFICA	TE OF MAILING	-		
I hereby certify that this of	correspondence is				al Service as	first class mail in an envel	

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be send to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



re Application of:

Examiner:

Unassigned

Thierry Glauser et al.

Serial No.

10/807,362

Art Unit:

1615

Filed:

March 22, 2004

Title:

Phosphoryl Choline Coating Compositions

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. §§1.97-1.98

Dear Examiner:

In accordance with the duty of disclosure under 37 C.F.R. §1.56 and pursuant to 37 C.F.R. §§1.97-1.98, Applicants hereby notify the U.S. Patent and Trademark Office of the references listed on the attached Form PTO-1449. According to a Notice signed July 11, 2003, the U.S. Patent and Trademark Office has waived the requirement under 37 C.F.R. § 1.98(a)(2)(i) for all patent applications filed after June 30, 2003. *See*, 1276 Off. Gaz. Pat. Office 55. Since this patent application was filed after June 30, 2003, Applicants have not provided copies of the cited U.S. patents or the U.S. Patent Application Publications. Copies of the cited foreign patent documents and other non-patent documents have been submitted herewith.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicants reserve the right to dispute the listed documents as prior art during examination. Furthermore, Applicants do not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application. The submission of this Information Disclosure Statement is not to be construed as a representation that a search has been made or that no other material information may exist.

1

The Examiner is requested to initial the enclosed Form PTO-1449 and return a copy thereof to the undersigned.

The present Information Disclosure Statement is being filed before receiving the first Office Action. Therefore, no certification under 37 C.F.R. §1.97(e) or fee under 37 C.F.R. §1.17(p) is required. However, the Commissioner is authorized to charge any deficiencies or other amounts due to Deposit Account No. 07-1850.

Date: <u>July</u> 8, 2004

SQUIRE, SANDERS & DEMPSEY L.L.P. One Maritime Plaza, Suite 300 San Francisco, CA 94111 Telephone (415) 954-0200 Facsimile (415) 393-9887 Respectfully submitted,

Zhaoyang Li, Ph.D. Attorney for Applicant Reg. No. 46,872 FORM PTO-1449 (Modified)

US DEPARTMENT OF COMMERCE | Docket No.

Approved for use through 10/31/2002 US Patent and Tradema

INFORMATION DISCLOSURE CITATION

US Patent and Trademark Office

50623.351

Application No. 10/807,362

in an Application

Applicant

Glauser et al.

JUL 1 2 2004 ...

Group Art Linit Filing Date

	7 7004 33 33 33 33 33 33 33 33 33 33 33 33 33	(Use several sheets if	necessary)	Filing Date March 22, 2004		roup Art Unit 1	615
Examiner	- ARTS		U.S. PATE	ENT DOCUMENTS			010
Examiner Initial	Ref. No.	Document Number	Date of Patent	Name	Class	Subclass	Filing Date if Appropriate
	A1	4,329,383	5/11/82	Joh	428	36	7/21/80
	A2	4,613,665	9/23/86	Larm	536	20	2/8/83
	А3	4,733,665	3/29/88	Palmaz	128	343	11/7/85
	A4	4,800,882	1/31/89	Gianturco	128	343	3/13/87
	A5	4,882,168	11/21/89	Casey et al.	424	468	9/5/86
	A6	4,886,062	12/12/89	Wiktor	128	343	10/19/87
	A7	4,916,193	4/10/90	Tang et al.	525	413	8/1/88
	A8	4,941,870	7/17/90	Okada et al.	600	36	12/30/88
·	A9	4,977,901	12/18/90	Ofstead	128	772	4/6/90
	A10	4,994,071	2/19/91	MacGregor	606	194	5/22/89
	A11	5,092,877	3/3/92	Pinchuk	623	1	7/5/90
	A12	5,112,457	5/12/92	Marchant	204	165	7/23/90
	A13	5,163,952	11/17/92	Froix	623	1	9/14/90
	A14	5,165,919	11/24/92	Sasaki et al.	424	488	9/26/90
	A15	5,182,317	1/26/93	Winters et al.	523	112	6/17/91
	A16	5,262,451	11/16/93	Winters et al.	523	112	7/5/88
	A17	5,272,012	12/21/93	Opolski	428	423.1	1/29/92
	A18	5,292,516	3/8/94	Viegas et al.	424	423	11/8/91
	A19	5,298,260	3/29/94	Viegas et al.	424	486	6/9/92
	A20	5,300,295	4/5/94	Viegas et al.	424	427	9/13/91
	A21	5,304,121	4/19/94	Sahatjian	604	53	11/22/91
	A22	5,306,501	4/26/94	Viegas et al.	424	423	11/8/91
	A23	5,328,471	7/12/94	Slepian	604	101	8/4/93
	A24	5,330,768	7/19/94	Park et al.	424	501	7/5/91
	A25	5,338,770	8/16/94	Winters et al.	523	112	4/12/90
	A26	5,380,299	1/10/95	Fearnot et al.	604	265	8/30/93

	A27	5,417,981	5/23/95	Endo et al.	424	486	4/28/93
	A28	5,447,724	9/5/95	₄Helmus et al.	424	426	11/15/93
	A29	5,455,040	10/3/95	Marchant	424	426	11/19/92
	A30	5,462,990	10/31/95	Hubbell et al.	525	. 54.1	10/5/93
	A31	5,464,650	11/7/95	Berg et al.	427	2.30	4/26/93
	A32	5,569,463	10/29/96	Helmus et al.	424	426	6/7/95
	A33	5,578,073	11/26/96	Haimovich et al.	623	1	9/16/94
	A34	5,605,696	2/25/97	Eury et al.	424	423	3/30/95
	A35	5,609,629	3/11/97	Fearnot et al.	623	1	6/7/95
	A36	5,624,411	4/29/97	Tuch	604	265	6/7/95
	A37	5,628,730	5/13/97	Shapland et al.	604	21	7/18/94
	A38	5,649,977	7/22/97	Campbell	623	1	9/22/94
	A39	5,658,995	8/19/97	Koḥn et al.	525	432	11/27/95
	A40	5,667,767	9/16/97	Greff et al.	424	9.411	7/27/95
	A41	5,670,558	9/23/97	Onishi et al.	523	112	7/6/95
	A42	5,679,400	10/21/97	Tuch	427	2.14	6/7/95
	A43	5,700,286	12/23/97	Tartaglia et al.	623	1	8/22/96
	A44	5,702,754	12/30/97	Zhong	427	2.12	2/22/95
	A45	5,716,981	2/10/98	Hunter et al.	514	449	6/7/95
	A46	5,735,897	4/7/98 .	Buirge	623	12	1/2/97
·	A47	5,746,998	5/5/98	Torchilin et al.	424	9.4	8/8/96
	A48	5,776,184	7/7/98	Tuch	623	1	10/9/96
	A49	5,788,979	8/4/98	Alt et al.	424	426	2/10/97
	A50	5,800,392	9/1/98	Racchini	604	96	5/8/96
	A51	5,820,917	10/13/98	Tuch	427	2.1	6/7/95
	A52	5,824,048	10/20/98	Tuch	623	1	10/9/96
	A53	5,824,049	10/20/98	Ragheb et al.	623	1	10/31/96
	A54	5,830,178	11/3/98	Jones et al.	604	49	10/11/96
	A55	5,837,008	11/17/98	Berg et al.	623	1	4/27/95
	A56	5,837,313	11/17/98	Ding et al.	427	2.21	6/13/96
	A57	5,851,508	12/22/98	Greff et al.	424	9.411	2/14/97
	A58	5,858,746	1/12/99	Hubbell et al.	435	177	1/25/95

	A59	5,865,814	2/2/99	Tuch	604	265	8/6/97
	A60	5,869,127	2/9/99	Zhong	427	2.12	6/18/97
	A61	5,873,904	2/23/99	Ragheb et al.	623	1	2/24/97
·	A62	5,876,433	3/2/99	Lunn	623	1	5/29/96
	A63	5,877,224	3/2/99	Brocchini et al.	514	772.2	7/28/95
	A64	5,925,720	7/20/99	Kataoka et al.	525	523	12/18/97
	A65	5,955,509	9/21/99	Webber et al.	514	772.7	4/23/97
	A66	5,971,954	10/26/99	Conway et al.	604	96	1/29/97
	A67	5,980,928	11/9/99	Terry	424	427	7/29/97
	A68	5,980,972	11/9/99	Ding	427	2.24	9/22/97
	A69	5,997,517	12/7/99	Whitbourne	604	265	1/27/97
	A70	6,010,530	1/4/00	Goicoechea	623	1	2/18/98
	A71	6,015,541	1/18/00	Greff et al.	424	1.25	11/3/97
	A72	6,033,582	3/7/00	Lee et al.	216	37	1/16/98
	A73	6,042,875	3/28/00	Ding et al.	427	2.24	3/2/99
	A74	6,051,648	4/18/00	Rhee et al.	525	54.1	1/13/99
·	A75	6,051,576	4/18/00	Ashton et al.	514	255	1/29/97
	A76	6,056,993	5/2/00	Leidner et al.	427	2.25	4/17/98
	A77	6,060,451	5/9/00	DiMaio et al.	514	13	3/20/95
	A78	6,060,518	5/9/00	Kabanov et al.	514	781	8/16/96
	A79	6,080,488	6/27/00	Hostettler et al.	428	423.3	3/24/98
	A80	6,096,070	8/1/00	Ragheb et al.	623	1	5/16/96
	A81	6,099,562	8/8/00	Ding et al.	623	1.46	12/22/97
	A82	6,110,188	8/29/00	Narciso, Jr.	606	153	3/9/98
	A83	6,110,483	8/29/00	Whitbourne et al.	424	423	6/23/97
	A84	6,113,629	9/5/00	Ken	623	1.1	5/1/98
	A85	6,120,536	9/19/00	Ding et al.	623	1.43	6/13/96
	A86	6,120,904	9/19/00	Hostettler et al.	428	423.3	5/24/99
<u> </u>	A87	6,121,027	9/19/00	Clapper et al.	435	180	8/15/97
	A88	6,129,761	10/10/00	Hubbell	623	11	6/7/95
	A89	6,153,252	11/28/00	Hossainy et al.	427	2.3	4/19/99
	A90	6,165,212	12/26/00	Dereume et al.	623	1.13	6/28/99

			·			
A91	6,203,551	3/20/01	Wu	606	108	10/4/99
A92	6,231,600	5/15/01	Zhong	623	1.42	5/26/99
 A93	6,240,616	6/5/01	Yan	29	527.2	4/15/97
A94	6,245,753	6/12/01	Byun et al.	514	56	4/27/99
A95	6,251,136	6/26/01	Guruwaiya et al.	623	1.46	12/8/99
A96	6,254,632	7/3/01	Wu et al.	623	1.15	9/28/00
A97	6,258,121	7/10/01	Yang et al.	623	1.46	7/2/99
A98	6,283,947	9/4/01	Mirzaee	604	264	7/13/99
A99	6,283,949	9/4/01	Roorda	604	288.02	12/27/99
A100	6,284,305	9/4/01	Ding et al.	427	2.28	5/18/00
A101	6,287,628	9/11/01	Hossainy et al.	427	2.3	9/3/99
 A102	6,299,604	10/9/01	Ragheb et al.	604	265	8/20/99
A103	6,306,176	10/23/01	Whitbourne	623	23.59	9/21/99
A104	6,331,313	12/18/01	Wong et al.	424	427	10/22/99
A105	6,335,029	1/1/02	Kamath et al.	424	423	12/3/98
 A106	6,346,110	2/12/02	Wu	606	108	1/3/01
A107	6,358,556	3/19/02	Ding et al.	427	2.24	1/23/98
A108	6,379,381	4/30/02	Hossainy et al.	623	1.42	9/3/99
A109	6,395,326	5/28/02	Castro et al.	427	2.24	5/31/00
A110	6,419,692	7/16/02	Yang et al.	623	1.15	2/3/99
A111	6,451,373	9/17/02	Hossainy et al.	427	2.25	8/4/00
A112	6,494,862	12/17/02	Ray et al.	604	96.01	12/30/99
A113	6,503,556	1/7/03	Harish et al.	427	2.24	12/28/00
A114	6,503,954	1/7/03	Bhat et al.	514	772.2	7/21/00
A115	6,506,437	1/14/03	Harish et al.	427	2.25	10/17/00
A116	6,527,801	3/4/03	Dutta	623	1.46	4/13/00
A117	6,527,863	3/4/03	Pacetti et al.	118	500	6/29/01
A118	6,540,776	4/1/03	Sanders Millare et al.	623	1.15	12/28/00
A119	6,544,223	4/8/03	Kokish	604	103.01	1/5/01

				·				
	A120	6,544,543	4/8/03	Mandrusov et al.	424	422	12/2	7/00
	A121	6,544,582	4/8/03	Yoe	427	2.24	1/5	6/01
	A122	6,555,157	4/29/03	Hossainy	427	2.24	7/2	5/00
	A123	6,558,733	5/6/03	Hossainy et al.	427	2.24	10/2	6/00
	A124	6,565,659	5/20/03	Pacetti et al.	118	500	6/2	B/01
	A125	6,572,644	6/3/03	Moein	623	1.11	6/2	7/01
	A126	6,585,765	7/1/03	Hossainy et al.	623	1.45	6/2	9/00
	A127	6,585,926	7/1/03	Mirzaee	264	400	8/3	1/00
	A128	6,605,154	8/12/03	Villareal	118	500	5/3	1/01
	[]		<u> </u>	ION PUBLICATION DOCUM	<u> </u>			
Examiner	Ref. No.	Document	Date of	Name	Class	Subclass	Filing	Date if
Initial		Number	Publication	·	<u> </u>		_	priate
	A129	2001/0018469	8/30/01	Chen et al.	523	121	12/2	8/00
	A130	2001/0037145	11/1/01	Guruwaiya et al.	623	1.15	6/2	1/01
	A131	2002/0077693	6/20/02	Barclay et al.	623	1.13	12/19/00	
	A132	2002/0091433	7/11/02	Ding et al.	623	1.2	12/1	7/01
	A133	2002/0155212	10/24/02	Hossainy	427	2.25	4/24	4/01
	A134	2003/0065377	4/3/03	Davila et al.	623	1.13	4/30	0/02
	A135	2003/0099712	5/29/03	Jayaraman	424	486	11/2	6/01
			FOREIGN PA	ATENT DOCUMENTS	-	,	_	
Examiner Initial	Ref. No.	Document Number	Date of Publication	Country	Class	Subclass	Trans Yes	lation No
maa	B1	EP 0 301 856	2/1/89	European				1.00
	B2	EP 0 514 406	11/25/92	European	-			
	ВЗ	EP 0 604 022	6/29/94	European				
	B4	EP 0 623 354	11/9/94	European			•	
	B5	EP 0 665 023	8/2/95	European				
	В6	EP 0 701 802	3/20/96	European				
	В7	EP 0 716 836	6/19/96	European				Ĩ
	В8	EP 0 809 999	12/3/97	European				
	В9	EP 0 832 655	4/1/98	European				
	B10	EP 0 850 651	7/1/98	European				
	B11	EP 0 879 595	11/25/98	European				
	B12	EP 0 910 584	4/28/99	European				
	•					-		

B13	EP 0 923 953	6/23/99	European	•	
B14	EP 0 953 320	11/3/99	European		
B15	EP 0 970 711	1/12/00	European		
B16	EP 0 982 041	3/1/00	European		
B17	EP 1 273 314	1/8/03	European		
B18	2001-190687	7/17/01	Japan (Abstract)		х
B19	WO 91/12846	9/5/91	PCT		
B20	WO 95/10989	4/27/95	PCT		
B21	WO 96/40174	12/19/96	PCT		
B22	WO 97/10011	3/20/97	PCT		
B23	WO 97/45105	12/4/97	PCT		
B24	WO 97/46590	12/11/97	PCT		
B25	WO 98/17331	4/30/98	PCT		
B26	WO 98/36784	8/27/98	PCT		
B27	WO 99/01118	1/14/99	PCT		
B28	WO 99/38546	8/5/99	PCT		
B29	WO 99/63981	12/16/99	PCT		
B30	WO 00/02599	1/20/00	PCT		
B31	WO 00/12147	3/9/00	PCT		
B32	WO 00/18446	4/6/00	PCT		
B33	WO 00/64506	11/2/00	PCT		
B34	WO 01/01890	1/11/01	PCT		
B35	WO 01/15751	3/8/01	PCT		
B36	WO 01/17577	3/15/01	PCT		
B37	WO 01/45763	6/28/01	PCT		
B38	WO 01/49338	7/12/01	PCT		
B39	WO 01/74414	10/11/01	PCT		
B40	WO 02/03890	1/17/02	PCT		
B41	WO 02/026162	4/4/02	PCT		
B42	WO 02/34311	5/2/02	PCT		
B43	WO 02/056790	7/25/02	PCT		

	B44	WO 03/000308	1/3/03	PCT			<u> </u>	
	B45	WO 03/022323	3/20/03	PCT		-		
	B46	WO 03/028780	4/10/03	PCT		 		
	B47	WO 03/037223	5/8/03	PCT				
	B48	WO 03/039612	5/15/03	PCT		-		
				luding Author, Title, Date, Pertinent I	Pages, etc.)	, l		
	C1			the Dream Stent, Clinica 710:15 (ht?reg=1061848202959, printed 8				
	C2			complications by 30%, Clinica 73 ht?req=1061847871753, printed 8			5),	·—
	С3	Anonymous, <i>Rolling</i> (Abstract 434009), Re		Loading Device for Therapeutic 4-975 (June 2000).	Agent Deliv	very or Co	oated St	ent
	C4			ninate cardiology, Clinica 720:22 (ht?req=1061848017752, printed 8				
	C5	Aoyagi et al., <i>Prepara</i> Journal of Controlled		ed aliphatic polyester and applicat 5 (1994).	ion to therr	mo-respoi	nsive ma	aterial,
	C6	Barath et al., Low Doi Injury, JACC 13(2): 2		gents Prevents Smooth Muscle C eb. 1989).	ell Prolifera	ation After	Endoth	elial
	C7	Barbucci et al., <i>Coatii</i> Mater. Res. 25:1259-		y available materials with a new h	eparinizab	le materia	l, J. Bio	med.
	C8	Chung et al., <i>Inner co</i> Journal of Controlled		n for drug delivery control of theri 3 (2000).	mo-respons	sive polyn	neric mi	celles,
· · · · · · · · · · · · · · · · · · ·	C9			the Arterial Wall Via Polyurethane leterization and Cardiovascular D				
	C10	Dichek et al., Seeding 80(5):1347-1353 (Nov		Stents with Genetically Engineere	ed Endothe	lial Cells,	Circ.	
	C11			elivery from a Polymer Coated Re n, JACC, 4A (701-1), Abstract (Fe		Metallic St	ent: Kind	etics,
	C12	Gravlee, <i>Heparin-Coa</i> Anesthesia, Vol. 8, No	•	nary Bypass Circuits, Journal of C (1994).	Cardiothora	cic and V	ascular	
	C13	Helmus, <i>Medical Dev</i> SAMPE Technical Co		stems Approach: Central Venous 8, 1990.	Catheteres	s, 22 nd Int	ernation	al
	C14							
	C15	Herdeg et al., <i>Antipro</i> . 3:197-199 (1998).	liferative Stent Co	atings: Taxol and Related Compo	ounds, Sen	nin. Interv	ent. Car	diol.
	C16	Hubbell, <i>Pharmacolog</i> 127S (1993).	gic Modification of	Materials, Cardiovascular Pathol	ogy, Vol. 2	, No. 3 (S	uppl.), 1	21S-
	C17			oligo(methyl methacrylate) and po of Controlled Release 51:221-229		acid) for n	nicellar ———	
	C18	Kataoka et al., <i>Block</i> (24:119-132 (1993).	copolymer micelle	s as vehicles for drug delivery, Jo	ournal of C	ontrolled	Release	1
	C19			rial Restenosis Using Polymeric Chem. Soc. Symp.], pp. 259-268 (Release I	mplants 	,
·	C20	Liu et al., <i>Drug releas</i> 68:167-174 (2000).	e characteristics o	of unimolecular polymeric micelle	s, Journal o	of Control	ed Rele	ase
SanFrancisc	140004	o 4						

	C21	Marconi et al., Covalent bonding of heparin to a vinyl copolymer for biomedical applications, Biomaterials 18(12):885-890 (1997).				
	C22	Matsumaru et al., Embolic Materials For Endovascular Treatment of Cerebral Lesions, J. Biomater. Sci. Polymer Edn 8(7):555-569 (1997).				
	C23	Miyazaki et al., Antitumor Effect of Implanted Ethylene-Vinyl Alcohol Copolymer Matrices Containing Anticancer Agents on Ehrlich Ascites Carcinoma and P388 Leukemia in Mice, Chem. Pharm. Bull. 33(6) 2490-2498 (1985).				
	C24	Miyazawa et al., Effects of Pemirolast and Tranilast on Intimal Thickening After Arterial Injury in the Rat, J. Cardiovasc. Pharmacol., pp. 157-162 (1997).				
	C25	Nordrehaug et al., A novel biocompatible coating applied to coronary stents, European Heart Journal 14, p 321 (P1694), Abstr. Suppl. (1993).				
	C26	Ohsawa et al., Preventive Effects of an Antiallergic Drug, Pemirolast Potassium, on Restenosis After Percutaneous Transluminal Coronary Angioplasty, American Heart Journal 136(6):1081-1087 (Dec. 1998)				
	C27	Ozaki et al., New Stent Technologies, Progress in Cardiovascular Diseases, Vol. XXXIX(2):129-140 (Sept./Oct. 1996).				
	C28	Pechar et al., Poly(ethylene glycol) Multiblock Copolymer as a Carrier of Anti-Cancer Drug Doxorubicin, Bioconjucate Chemistry 11(2):131-139 (Mar./Apr. 2000).				
	C29	Peng et al., Role of polymers in improving the results of stenting in coronary arteries, Biomaterials 17:685-694 (1996).				
	C30	Shigeno, <i>Prevention of Cerebrovascular Spasm By Bosentan, Novel Endothelin Receptor</i> , Chemical Abstract 125:212307 (1996).				
	C31	van Beusekom et al., Coronary stent coatings, Coronary Artery Disease 5(7):590-596 (July 1994).				
	C32	Wilensky et al., <i>Methods and Devices for Local Drug Delivery in Coronary and Peripheral Arteries</i> , Trends Cardiovasc. Med. 3(5):163-170 (1993).				
	C33	Yokoyama et al., Characterization of physical entrapment and chemical conjugation of adriamycin in polymeric micelles and their design for in vivo delivery to a solid tumor; Journal of Controlled Release 50:79-92 (1998).				
EXAMINER	•	DATE CONSIDERED				
		rerences considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered.				
Include copy of	of this form	with next communication to applicant.				